The Investigation of Carnitine Profile Before and After Coronary Angiography in Coronary Artery Patients
Carnitine and Cardiovascular Diseases
DOI:
https://doi.org/10.5281/zenodo.12574936Keywords:
Coronary artery disease, Carnitine profile, Coronary Angiography, LCMS/MSAbstract
Objective: Alterations in carnitine profile may play a role in the pathogenesis of cardiovascular diseases. This study was carried out to identify new markers that can be used in the diagnosis and treatment of cardiovascular diseases by comparing the free carnitine profile of coronary artery patients and normal individuals.
Material and Methods: In our study, 25 patients with coronary artery disease (treatment group) and 25 healthy volunteers (control group), totaling 50 individuals were included in the study. The carnitine profile in dry blood samples obtained from 25 individuals with coronary artery disease before and after coronary angiography was compared with the dry blood carnitine profile obtained from 25 healthy individuals. The free carnitine profile of the plasma samples was analyzed by LCMS8040. The results were evaluated statistically.
Results: In our study, 27 parameters in the carnitine profile (C0, C2, C3, C4, C4DC, C5, C5:1, C5OH, C5DC, C6, C6DC, C8, C8:1, C8DC, C10, C10:1, C10DC, C12, C14, C14:1, C14:2, C16, C16:1, C18, C18:1, C18:2, C18:1 OH) were examined in accordance with the LCMS/MS method. According to the results obtained; The values of C0, C2, C3, C4, C4DC, C5, C5:1, C5OH, C5OH, C14 and C16 parameters in the pre-angiography group of coronary artery patients were found to be higher than the control group. It was considered statistically significant (p<0.05).
Discussion and Conclusion: According to our results, we suggest that free carnitine profile has the potential to be used in the diagnosis and treatment of coronary artery disease.
References
Shao C, Wang J, Tian J, Tang YD. Coronary Artery Disease: From Mechanism to Clinical Practice. Adv Exp Med Biol. 2020;1177:1-36.
Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407–77.
Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al. Heart disease and stroke statistics-2021 update: a report from the American Heart Association. Circulation. 2021; 143(8):e254-e743.
Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al: 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012; 60(24):e44-e164.
Stefanini GG, Malanchini G, Sousa-Uva M, Neumann FJ. What's new in the 2018 ESC/EACTS guidelines on myocardial revascularization?. G Ital Cardiol (Rome). 2018;19(11 Suppl 2):5S-9S.
Demir Ö, Arslantaş H. The Effects of Progressive Relaxation Exercises Applied with Music Before Coronary Angiography and Percutaneous Transluminal Coronary Angioplasty on the State and Trait Anxiety of People. Journal of Psychiatric Nursing. 2014;5(3):113-121.
Atabilen B, Yıldıran H. The Use of Carnitine in Hemodialysis Patients. Turk Neph Dial Transpl. 2017;26(3):246-253.
La Marca G, Malvagia S, Pasquini E, Innocenti M, Fernandez MR, Donati MA, et al. The inclusion of succinylacetone as marker for tyrosinemia type i in expanded newborn screening programs. Rapid Commun Mass Spectrom. 2008;22(6):812-8.
Azzari C, La Marca G, Resti M. Neonatal screening for severe combined immunodeficiency caused by an adenosine deaminase defect: a reliable and inexpensive method using tandem mass spectrometry. J. of Allergy and Clinical Immunology. 2011;127(6):1394-9.
Rasmussen J, Duno M, Lund AM, Steuerwald U,Hansen SH, Joensen HD, et al. Increased risk of sudden death in untreated primary carnitine deficiency. J Inherit Metab Dis. 2020;43(2):290‐96.
Crefcoeur LL, Melles MC, Bruning TA, Pereira RR, Langendonk JG. Primary carnitine deficiency is a life-long disease. JIMD Rep. 2022;63(6):524-28.
Trupp RJ, Abraham WT. Congestive heart failure. In: Rakel RE, Bope ET, eds, Rakel: Conn’s Current Therapy. 54th ed. New York, WB. Saunders Company. 2002.pp.306-313
Wang ZY, Liu YY, Liu GH, Lu HB, Mao CY. l-Carnitine and heart disease. Life Sci. 2018;194:88-97.
Hu Z, Zhu Z, Cao Y, Wang L, Sun X, Dong J, et.al. Rapid and sensitive differentiating ischemic and hemorrhagic strokes by dried blood spot based direct injection mass spectrometry metabolomics analysis. Journal of clinical laboratory analysis. 2016;30(6):823-30.
Morris CR, Agin, MC. Syndrome of allergy, apraxia, and malabsorption: characterization of a neurodevelopmental phenotype that responds to omega 3 and vitamin E supplementation. Alternative Therapies in Health & Medicine. 2009;15(4):34.
Koyuncu İ, Gonel A. Rapid and sensitive determination of carnitine profiling by tandem mass spectrometry can be a diagnostic marker of paroxysmal atrial fibrillation. Journal of Clınıcal and Analytıcal Medicine. 2018;9(5):447-51.
Broderick TL, Quinney HA, Barker CC, Lopaschuk GD. Beneficial effect of carnitine on mechanical recovery of rat hearts reperfused after a transient period of global ischemia is accompanied by a stimulation of glucose oxidation. Circulation. 1993;87(3): 972-81.
Goetzman ES. Advances in the Understanding and Treatment of Mitochondrial Fatty Acid Oxidation Disorders. Current Genetic Medicine Reports. 2017;5(3):132-42.
Mondillo S, Faglia S, D'Aprile N, Mangiacotti L, Campolo MA, Palazzuoli V. Therapy of arrhythmia induced by myocardial ischemia. Association of L-carnitine, propafenone and mexiletine. La Clinica Terapeutica. 1995;146(12):769-74.
Hunter WG, Kelly JP, McGarrah 3rd RW, Khouri MG, Craig D, Haynes C, et.al. Metabolomic profiling identifies novel circulating biomarkers of mitochondrial dysfunction differentially elevated in heart failure with preserved versus reduced ejection fraction: evidence for shared metabolic impairments in clinical heart failure. J Am Heart Assoc. 2016;5(8): e003190.
Dikme R, Padak M, Işık M, Koyuncu İ, Temiz E, Aydın MS, et al. Soluble ST2 as a Potential Biomarker in Pericardial Fluid of Coronary Artery Patients. Braz J Cardiovasc Surg. 2021;36(5):677-684.
Malakar AK, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S. A review on coronary artery disease, its risk factors, and therapeutics. J Cel physiol, 2019;234(10):16812.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 MEHES JOURNAL
![Creative Commons License](http://i.creativecommons.org/l/by/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution 4.0 International License.